A multi-arm, multicenter Phase 1 Alzheimer’s trial is no small feat. But when a biotechnology sponsor needed to study safety, PK, and early efficacy signals in patients with mild cognitive impairment or early-stage Alzheimer’s, Clinilabs got it done.
In this case study, explore how Clinilabs:
- Activated 17 U.S. sites and screened 260 patients, randomizing 65 within 18 months
- Delivered high-quality imaging and data, even across eight protocol amendments
- Enabled rapid site activation, protocol adaptation, and top-line data presentation within 6 days of database lock
- Ensured diagnostic accuracy and safety with centralized ARIA monitoring
